Androgen receptor splice variant V7 (AR-V7) in circulating tumor cells: a coming of age for AR splice variants? (English)
- New search for: Sprenger, C.
- New search for: Uo, T.
- New search for: Plymate, S.
- New search for: Sprenger, C.
- New search for: Uo, T.
- New search for: Plymate, S.
In:
ANNALS OF ONCOLOGY
;
26
, 9
;
1805-1807
;
2015
-
ISSN:
- Article (Journal) / Print
-
Title:Androgen receptor splice variant V7 (AR-V7) in circulating tumor cells: a coming of age for AR splice variants?
-
Contributors:
-
Published in:ANNALS OF ONCOLOGY ; 26, 9 ; 1805-1807
-
Publisher:
- New search for: OXFORD UNIVERSITY PRESS
-
Publication date:2015-01-01
-
Size:3 pages
-
ISSN:
-
Type of media:Article (Journal)
-
Type of material:Print
-
Language:English
- New search for: 616.992
- Further information on Dewey Decimal Classification
-
Classification:
DDC: 616.992 -
Source:
© Metadata Copyright the British Library Board and other contributors. All rights reserved.
Table of contents – Volume 26, Issue 9
The tables of contents are generated automatically and are based on the data records of the individual contributions available in the index of the TIB portal. The display of the Tables of Contents may therefore be incomplete.
- 1805
-
Androgen receptor splice variant V7 (AR-V7) in circulating tumor cells: a coming of age for AR splice variants?Sprenger, C. / Uo, T. / Plymate, S. et al. | 2015
- 1808
-
Statistical controversies in clinical research: requiem for the 3 + 3 design for phase I trialsPaoletti, X. / Ezzalfani, M. / Le Tourneau, C. et al. | 2015
- 1813
-
Combining immunotherapy and anticancer agents: the right path to achieve cancer cure?Apetoh, L. / Ladoire, S. / Coukos, G. / Ghiringhelli, F. et al. | 2015
- 1824
-
A systematic review of immune-related adverse event reporting in clinical trials of immune checkpoint inhibitors†Chen, T. W. / Razak, A. R. / Bedard, P. L. / Siu, L. L. / Hansen, A. R. et al. | 2015
- 1830
-
A new generation of cancer genome diagnostics for routine clinical use: overcoming the roadblocks to personalized cancer medicineHeuckmann, J. M. / Thomas, R. K. et al. | 2015
- 1838
-
Implementation of supportive care and best supportive care interventions in clinical trials enrolling patients with cancer†Lee, R. T. / Ramchandran, K. / Sanft, T. / Von Roenn, J. et al. | 2015
- 1846
-
Patient-reported outcomes in routine cancer clinical practice: a scoping review of use, impact on health outcomes, and implementation factorsHowell, D. / Molloy, S. / Wilkinson, K. / Green, E. / Orchard, K. / Wang, K. / Liberty, J. et al. | 2015
- 1859
-
Serial blood-based analysis of AR-V7 in men with advanced prostate cancerNakazawa, M. / Lu, C. / Chen, Y. / Paller, C. J. / Carducci, M. A. / Eisenberger, M. A. / Luo, J. / Antonarakis, E. S. et al. | 2015
- 1865
-
Treatment outcome and patterns of relapse following adjuvant carboplatin for stage I testicular seminomatous germ-cell tumour: results from a 17-year UK experienceChau, C. / Cathomas, R. / Wheater, M. / Klingbiel, D. / Fehr, M. / Bennett, J. / Markham, H. / Lee, C. / Crabb, S. J. / Geldart, T. et al. | 2015
- 1871
-
Phase I/II study of S-1 in combination with sorafenib for metastatic renal cell carcinomaNaito, S. / Sakai, H. / Hashine, K. / Tomita, Y. / Shinohara, N. / Fujisawa, M. / Eto, M. / Ozono, S. / Akaza, H. et al. | 2015
- 1877
-
Final overall survival results from a randomised, phase III study of erlotinib versus chemotherapy as first-line treatment of EGFR mutation-positive advanced non-small-cell lung cancer (OPTIMAL, CTONG-0802)Zhou, C. / Wu, Y. L. / Chen, G. / Feng, J. / Liu, X. Q. / Wang, C. / Zhang, S. / Wang, J. / Zhou, S. / Ren, S. et al. | 2015
- 1883
-
First-line erlotinib versus gemcitabine/cisplatin in patients with advanced EGFR mutation-positive non-small-cell lung cancer: analyses from the phase III, randomized, open-label, ENSURE study†Wu, Y. L. / Zhou, C. / Liam, C. K. / Wu, G. / Liu, X. / Zhong, Z. / Lu, S. / Cheng, Y. / Han, B. / Chen, L. et al. | 2015
- 1890
-
Prognostic and predictive value of ERβ1 and ERβ2 in the Intergroup Exemestane Study (IES)—first results from PathIES†Speirs, V. / Viale, G. / Mousa, K. / Palmieri, C. / Reed, S. N. / Nicholas, H. / Cheang, M. / Jassem, J. / Lønning, P. E. / Kalaitzaki, E. et al. | 2015
- 1898
-
Population-based analysis of the impact and generalizability of the NSABP-B24 study on endocrine therapy for patients with ductal carcinoma in situ of the breast†Lo, A. C. / Truong, P. T. / Wai, E. S. / Nichol, A. / Weir, L. / Speers, C. / Hayes, M. M. / Baliski, C. / Tyldesley, S. et al. | 2015
- 1904
-
Randomized, phase II, placebo-controlled trial of onartuzumab and/or bevacizumab in combination with weekly paclitaxel in patients with metastatic triple-negative breast cancerDiéras, V. / Campone, M. / Yardley, D. A. / Romieu, G. / Valero, V. / Isakoff, S. J. / Koeppen, H. / Wilson, T. R. / Xiao, Y. / Shames, D. S. et al. | 2015
- 1910
-
Derived neutrophil lymphocyte ratio may predict benefit from cisplatin in the advanced biliary cancer: the ABC-02 and BT-22 studiesGrenader, T. / Nash, S. / Plotkin, Y. / Furuse, J. / Mizuno, N. / Okusaka, T. / Wasan, H. / Valle, J. / Bridgewater, J. et al. | 2015
- 1916
-
Phase II/III study of second-line chemotherapy comparing irinotecan-alone with S-1 plus irinotecan in advanced gastric cancer refractory to first-line treatment with S-1 (JACCRO GC-05)Tanabe, K. / Fujii, M. / Nishikawa, K. / Kunisaki, C. / Tsuji, A. / Matsuhashi, N. / Takagane, A. / Ohno, T. / Kawase, T. / Kochi, M. et al. | 2015
- 1923
-
A phase II/III randomized study to compare the efficacy and safety of rigosertib plus gemcitabine versus gemcitabine alone in patients with previously untreated metastatic pancreatic cancer†O'Neil, B. H. / Scott, A. J. / Ma, W. W. / Cohen, S. J. / Aisner, D. L. / Menter, A. R. / Tejani, M. A. / Cho, J. K. / Granfortuna, J. / Coveler, L. et al. | 2015
- 1930
-
Survival after resection of perihilar cholangiocarcinoma—development and external validation of a prognostic nomogramGroot Koerkamp, B. / Wiggers, J. K. / Gonen, M. / Doussot, A. / Allen, P. J. / Besselink, M. G. / Blumgart, L. H. / Busch, O. R. / D'Angelica, M. I. / DeMatteo, R. P. et al. | 2015
- 1936
-
Prognostic role of the LCS6 KRAS variant in locally advanced rectal cancer: results of the EXPERT-C trialSclafani, F. / Chau, I. / Cunningham, D. / Peckitt, C. / Lampis, A. / Hahne, J. C. / Braconi, C. / Tabernero, J. / Glimelius, B. / Cervantes, A. et al. | 2015
- 1941
-
Cetuximab, docetaxel, and cisplatin as first-line treatment in patients with recurrent or metastatic head and neck squamous cell carcinoma: a multicenter, phase II GORTEC studyGuigay, J. / Fayette, J. / Dillies, A. F. / Sire, C. / Kerger, J. N. / Tennevet, I. / Machiels, J. P. / Zanetta, S. / Pointreau, Y. / Bozec Le Moal, L. et al. | 2015
- 1948
-
Comparison of EP2006, a filgrastim biosimilar, to the reference: a phase III, randomized, double-blind clinical study in the prevention of severe neutropenia in patients with breast cancer receiving myelosuppressive chemotherapyBlackwell, K. / Semiglazov, V. / Krasnozhon, D. / Davidenko, I. / Nelyubina, L. / Nakov, R. / Stiegler, G. / Singh, P. / Schwebig, A. / Kramer, S. et al. | 2015
- 1953
-
Indicators of integration of oncology and palliative care programs: an international consensusHui, D. / Bansal, S. / Strasser, F. / Morita, T. / Caraceni, A. / Davis, M. / Cherny, N. / Kaasa, S. / Currow, D. / Abernethy, A. et al. | 2015
- 1960
-
High anabolic potential of essential amino acid mixtures in advanced nonsmall cell lung cancerEngelen, M. P. / Safar, A. M. / Bartter, T. / Koeman, F. / Deutz, N. E. et al. | 2015
- 1966
-
Planning and reporting of quality-of-life outcomes in cancer trialsSchandelmaier, S. / Conen, K. / von Elm, E. / You, J. J. / Blümle, A. / Tomonaga, Y. / Amstutz, A. / Briel, M. / Kasenda, B. et al. | 2015
- 1974
-
Association between information provision and decisional conflict in cancer patientsSim, J. A. / Shin, J. S. / Park, S. M. / Chang, Y. J. / Shin, A. / Noh, D. Y. / Han, W. / Yang, H. K. / Lee, H. J. / Kim, Y. W. et al. | 2015
- 1980
-
The status of PD-L1 and tumor-infiltrating immune cells predict resistance and poor prognosis in BRAFi-treated melanoma patients harboring mutant BRAFV600Massi, D. / Brusa, D. / Merelli, B. / Falcone, C. / Xue, G. / Carobbio, A. / Nassini, R. / Baroni, G. / Tamborini, E. / Cattaneo, L. et al. | 2015
- 1987
-
Pazopanib in pretreated advanced neuroendocrine tumors: a phase II, open-label trial of the Spanish Task Force Group for Neuroendocrine Tumors (GETNE)†Grande, E. / Capdevila, J. / Castellano, D. / Teulé, A. / Durán, I. / Fuster, J. / Sevilla, I. / Escudero, P. / Sastre, J. / García-Donas, J. et al. | 2015
- 1994
-
Digital PCR quantification of MGMT methylation refines prediction of clinical benefit from alkylating agents in glioblastoma and metastatic colorectal cancerBarault, L. / Amatu, A. / Bleeker, F. E. / Moutinho, C. / Falcomatà, C. / Fiano, V. / Cassingena, A. / Siravegna, G. / Milione, M. / Cassoni, P. et al. | 2015
- 2000
-
Cross-over—it's a feature, not a bugEngelsberg, A. et al. | 2015
- 2003
-
Flaws in the trial design of IFCT-0802Gyawali, B. / Shimokata, T. / Honda, K. / Ando, Y. et al. | 2015
- 2003
-
Does activity of anticancer drugs in advanced cancer always translates in effectivity in early-stage high-risk disease?Schrijvers, D. L. et al. | 2015